Nascent Biotech, Inc.
NBIO · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | – | -100% | 33.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $1 | $1 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $0 | $1 | $0 | $0 |
| G&A Expenses | $2 | $2 | $1 | $2 |
| SG&A Expenses | $2 | $2 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $1 | $2 |
| Operating Income | -$2 | -$2 | -$0 | -$1 |
| % Margin | – | – | -45.7% | -186.7% |
| Other Income/Exp. Net | $0 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$2 | -$3 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$0 | -$1 |
| % Margin | – | – | -47% | -127.9% |
| EPS | -0.013 | -0.024 | -0.004 | -0.013 |
| % Growth | 43.2% | -436.4% | 66.9% | – |
| EPS Diluted | -0.013 | -0.024 | -0.004 | -0.013 |
| Weighted Avg Shares Out | 156 | 119 | 108 | 72 |
| Weighted Avg Shares Out Dil | 156 | 119 | 108 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $2 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $0 | $0 |
| EBITDA | $1 | -$1 | $0 | -$1 |
| % Margin | – | – | 1.7% | -80.4% |